Shots:

• The US FDA has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16- 18- 31- 33- 45- 52- and 58
• The FDA has approved the therapy under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. The continued approval for the indication may be contingent upon verification and description of clinical benefit in a confirmatory trial while the trial is undergoing
• Gardasil 9 is (human papillomavirus 9-valent vaccine- recombinant) is now approved for the prevention of HPV-related cervical- vaginal- vulvar- anal- oropharyngeal- and other head and neck cancers for females and males aged 9-45yrs.

Click here to read full press release/ article 

Ref: Merck | Image: Merck